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Abstract
Background: Advanced lung disease in adult cystic fibrosis (CF) drives most clinical care requirements. The aim was
to evaluate outcome (time to death while in the study) in a cohort of adult CF patients with severe lung disease,
and to determine the association among baseline patient characteristics and outcome.
Methods: A retrospective cohort study was performed and clinical records between 2000 and 2015 were reviewed.
Severe lung disease was defined as forced expiratory volume in the first second (FEV1) < 30% of predicted.
Outcomes of all patients, including their date of death or transplantation, were determined till January 1st, 2016.
Clinical data were recorded at the entry date.
Results: Among 39 subjects included in the study, 20 (51.3%) died, 16 (41.0%) underwent bilateral lung
transplantation, and 3 were alive at the end of the study period. Two variables were independently associated with
death: body mass index (BMI ≥ 18.5 kg/m2) (HR = 0.78, 95% CI = 0.64–0.96 and p = 0.017) and use of tobramycin
inhalation therapy (HR = 3.82, 95% CI = 1.38–10.6 and p = 0.010). Median survival was 37 (95% CI = 16.4–57.6)
months. The best cut-off point for BMI was 18.5 kg/m2. Median survival in patients with BMI < 18.5 kg/m2 was 36
months (95% CI = 18.7–53.3).
Conclusion: Median survival of CF subjects with FEV1 < 30% was 37 months. BMI and tobramycin inhalation therapy
were independently associated with death. Median survival in patients with BMI < 18.5 kg/m2 was significantly lower
than in patients with BMI ≥ 18.5 kg/m2. The association of tobramycin inhalation with death was interpreted as
confounding by severity (use was reserved for advanced lung disease).
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Background
Cystic fibrosis (CF) causes premature death [1]. The
prognosis of people with CF has improved considerably
over the past decades [2]. Data from a United States
registry show that the predicted median survival in CF is
currently 47.7 years of age [3]. Consequently, increasing
numbers of CF adults reaching middle age or older are
predicted for the future [4].
Lung disease is the strongest predictor of death in CF,
and forced expiratory volume in 1 second (FEV1) is the
main parameter used to assess the severity of lung dis-
ease in subjects with CF [5]. While a decline in lung
function is typical of almost all patients with CF, the rate
of decline is highly variable [6].
Although there is significant variation in pulmonary
outcomes by centre and birth cohort in both children
and adults, there is also variation based on mutation
class [3, 7].
Transplantation should be considered for suitable
patients with CF who have a 2-year predicted survival of
< 50% and who have functional limitations classified as
New York Heart Association Class III or IV [8].
Given the shortage of organs, the resulting waiting
times, and the unpredictable evolution of end-stage CF,
CF patients eligible for lung transplant should be re-
ferred to a transplant centre at an appropriate time [9].
An FEV1 < 30% of predicted values and/or a rapid de-
cline in FEV1 despite optimal conservative treatment
(particularly in a female patient), indicates timing of re-
ferral in CF. Other indicators for a pretransplant assess-
ment are malnutrition, diabetes, frequent exacerbations
and/or an increasing need for intravenous antibiotic
therapy, recurrent or massive haemoptysis, relapsing or
complicated pneumothorax, or the need for intensive
care unit admission [8, 9].
A significant number of CF patients with severe lung
disease (FEV1 < 30% of predicted) refuse or do not meet
the criteria for lung transplant. On the other hand, the
demand of lung transplantation continues to exceed the
supply of suitable donor organs and the median waiting
time for lung transplantation has increased [10]. Conse-
quently, CF patients with advanced lung disease will still
require clinical care of the adult CF team. Also, with re-
cent advances in the treatment of CF, patients with ad-
vanced pulmonary disease are living longer [11, 12].
Survival with advanced pulmonary disease presents new
questions and potential problems which are still being
formulated. So, it is important to perform a more de-
tailed study about the characteristics and outcomes of
this subgroup of patients.
The current study was therefore designed to evaluate
outcome (time to death while in the study) of a cohort
of adult CF patients with severe lung disease, seen at the
Adult CF Centre of Hospital de Clínicas de Porto Alegre
(HCPA), and to determine the association among base-
line patient characteristics and outcome.
Methods
Study design and population
This was a retrospective cohort study in which chart
review was conducted to identify patients with CF diag-
nosed with severe lung disease, evaluated, or monitored
at the Adult CF Centre of HCPA (Porto Alegre, Brazil).
Clinical records of Adult CF Program between 2000 and
2015 were reviewed. A cohort of those individuals with
severe lung disease defined as FEV1 < 30% of predicted
was analysed.
Hospital de Clínicas de Porto Alegre (HCPA) is a
tertiary care teaching hospital located in Porto Alegre,
the capital of the state of Rio Grande do Sul, in southern
Brazil. The Adult CF Centre of HCPA is one of the
largest adult CF centres in Brazil.
The diagnosis of CF should be based on clinical
features and a positive sweat chloride (> 60mmol/L) or,
in cases with a borderline sweat test result, the presence
of a known disease-causing mutation on each cystic
fibrosis transmembrane conductance regulator (CFTR)
gene [13].
For this survey, we reviewed our CF data base and
identified all patients who were, between January 1st,
2000 to December 31st, 2015, 18 years or older (adult
CF clinic receive patients 16 years or older). To more
specifically look at those patients with FEV1 < 30% of
predicted, we selected patients who had an FEV1 < 30%
predicted for the first time. It had to be persistently in
this range (defined as more than three subsequent mea-
sures < 30% predicted within a year, and who did not
have a subsequent value > 30% predicted on more than
one occasion. Also, patients had to be evaluated when
clinically stable, had not been hospitalized, and had no
changes in their treatment regimen for at least 30 days
before assessment. The date at which the patients met
these criteria for the first time (FEV1 < 30% predicted)
was defined as their “entry date” to create a life table for
the group.
The outcomes of all patients, including their date of
death or transplantation, were followed till January 1st,
2016. This date was defined as “the end of the study
period”.
Study measures and procedures
Data on the following variables were recorded at “the
entry date”: entry date, date of birth, sex, ethnicity,
educational level, income level monthly, presence of the
F508del mutation (homozygous or heterozygous), body
mass index (BMI), pancreatic status, CF related diabetes
(CFRD), history of pneumothorax, history of haemopty-
sis, history of previous diagnosis of allergic
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bronchopulmonary aspergillosis (ABPA), distal intestinal
obstruction syndrome (DIOS), CF liver disease, liver
transplant, chronic infection with Pseudomonas aerugi-
nosa, chronic infection with Burkholderia cepacia,
chronic infection with methicillin resistant Staphylococ-
cus aureus (MRSA), chronic infection with nontubercu-
lous mycobacteria (NTM), pulmonary artery systolic
pressure (PASP) estimated by Doppler echocardiog-
raphy, use of inhaled dornase alfa, use of inhaled colistin,
use of inhaled tobramycin, use of oral azithromycin,
pulmonary exacerbations in the last year, lung trans-
plantation status (listed, failed or refused).
In this study, pancreatic insufficiency was defined as
the use of enzymes and pancreatic sufficiency as no use
of enzymes. Chronic infection by P. aeruginosa, B.
cepacia or MRSA was defined as patients having three
or more positive isolates during the previous 12months.
CFRD was identified as use of insulin.
Ethics
The study was approved by the Ethics Committee of
Hospital de Clínicas de Porto Alegre and Plataforma
Brasil (protocol number 18–0055). Because this was a
retrospective study, the Ethics Committee waived the
need for informed consent. The authors signed a data
use agreement, protecting the confidentiality of patient
information. The clinical research complied with inter-
national and national standards for clinical study in
human (Declaration of Helsinki and Brazilian Govern-
mental regulation – Plataforma Brasil).
Statistical analysis
Data analysis was performed using the SPSS 22.0 (SPSS,
Chicago, Illinois). Descriptive statistics (mean ± SD,
range, n, and proportion) were calculated for character-
istics of the study sample.
Actuarial survival was determined by the Life Table
method. Kaplan-Meier graphs was used to demonstrate
survival over time. Patients who underwent lung trans-
plantation were censored at the time of their operation,
and patients who were alive were censored on the “the
end of the study period”.
Cox proportional hazards regression methods was
used to identify risk factors for death while on the study
and to determine the association among baseline patient
characteristics and outcomes. Time to death while in the
study was the primary outcome. Univariate proportional
hazards analyses were performed, and Wald chi-square
p values were calculated. The likelihood ratio method
was used to determine hazard ratios (HR), and the HR
was used to approximate the relative risk (RR).
Covariates with p < 0.1 entered into a forward stepwise
multivariate Cox regression analysis. A p value > 0.10
was the criterion to remove covariates from the model.
The non-collinear covariables that reached significance
(p < 0.1) in the univariate analysis were included in a
multivariate Cox regression analysis with enter method.
The most significant variable of this multivariate analysis
was correlated with the outcome (death) and submitted
to the receiver operating curve (ROC) to determine the
cut-off point.
Sample size calculation
We calculated sample size based on the study of Vizza
et al. [10] In this study, the actuarial survival rates for
the entire cohort were 59% at 3 year. Considering
survival rates of 59% at 3-year, margin of error = 16%,
confidence level = 95%, 37 subjects would be needed in
the study to show a meaningful survival curve.
Results
Between January 2000 to December 2015, 152 adult CF
patients were evaluated, or monitored at the Adult CF
Centre of HCPA. Out of them, 39 subjects were in-
cluded in the study. There were 27 (69.2%) male subjects
and 37 (94.9%) were Caucasian. The mean age at the
entry date was 25.3 ± 8.8 years. The mean FVC was
40.5 ± 10.3% of predicted and the mean FEV1 was
24.4% ± 3.9 of predicted (Tables 1 and 2).
Twenty subjects (51.3%) died (death outcome), 16 sub-
jects (41.0%) underwent bilateral lung transplantation
(censored at the date of transplantation), and 3 subjects
were alive and still waiting for lung transplantation at
the end of the study period (survival outcome). Among
those 20 subjects who died, 14 did not fulfil lung trans-
plantation criteria, 2 refused the lung transplantation re-
ferral and 4 died while waiting on waiting list. The time
spent on waiting list for those 4 subjects who died while
waiting for lung transplantation was 37.5 ± 10.6 months.
The time spent on waiting list for those 16 subjects who
underwent lung transplantation was 35.3 ± 24.9 months.
Additional descriptive characteristics are provided in
Tables 1, 2 and 3. None of these patients were on use of
CFTR modulators.
The results of univariate Cox proportional hazards re-
gression methods for death while on the study and the
association of case status (death) are shown in Table 1
for characteristics of subjects at the entry date; in Table
2 for pulmonary function tests, 6-min walk test (6MWT)
distance and PASP estimated by echocardiography at the
entry date; in Table 3 for therapeutic support at the
entry date. The following variables were significantly as-
sociated with case status (death): BMI kg/m2 (HR = 0.78,
95% CI = 0.64–0.96 and p = 0.017) and use of tobramycin
inhalation therapy (HR = 3.82, 95% CI = 1.38–10.6 and
p = 0.010). In multivariate Cox regression analysis with
enter method both variables were associated with case
status: BMI kg/m2 (HR = 0.82, 95% CI = 0.67–0.99 and
Silva et al. BMC Pulmonary Medicine          (2020) 20:194 Page 3 of 8
p = 0.038) and use of tobramycin inhalation therapy
(HR = 3.37, 95% CI = 1.20–9.46 and p = 0.021).
In ROC curve analysis for BMI, the area under the
curve was 0.694 and the best cut-off point selected was
18.5 kg/m2.
Figure 1a show Kaplan-Meier analysis of survival effect
in CF patients with FEV1 < 30%. Median survival was 37
(95% CI = 16.4–57.6) months and mean survival was
50.5 (95% CI = 39.3–61.6) months. Figure 1b shows
Kaplan-Meier survival functions comparing BMI < 18.5
Table 1 Characteristics of the patients at the entry date and associations with case status (death)
All Death Survival Transplant HR (95% CI) p-values
Subjects (n) 39 20 (51.3) 3 (7.7) 16 (41.0)
Sex, n (%) 0.84 (0.30–2.35) 0.743
Female 12 (30.8) 5 (25.0) 0 (0.0) 7 (43.8)
Male 27 (69.2) 15 (75.0) 3 (100.0) 9 (56.3)
Age (years) 25.3 ± 8.8 23.6 ± 8.7 41.7 ± 5.5 24.4 ± 6.1 0.98 (0.92–1.04) 0.456
Ethnicity – Caucasian (yes) 37 (94.9) 19 (51.4) 3 (8.1) 15 (40.5) 0.19 (0.02–1.63) 0.129
Age at diagnosis (years) 7.0 (11.8) 4.8 (7.8) 13.0 (12.5) 7 (16.2) 0.98 (0.93–1.04) 0.560
Educational level, n (%)
≤ 8 years 7 (17.9) 6 (30.0) 0 (0) 1 (6.3) – 0.639
> 8 years and < higher education 21 (53.8) 11 (55.0) 1 (33.3) 9 (56.3) 1.34 (0.32–5.6) 0.685
≥ higher education 11 (28.2) 3 (15.0) 2 (66.7) 6 (37.5) 0.81 (0.21–3.08) 0.760
Income level monthly, n (%)
≤ US$ 231 (≤ 3 BMW) 16 (41.0) 11 (55.0) 0 (0) 5 (31.3) – 0.270
> US$ 231 to US$ 693 (> 3 to 10 BMW) 12 (30.8) 4 (20.0) 2 (66.7) 6 (37.5) 1.45 (0.50–1.45) 0.500
> US$ 693 (> 10 BMW) 11 (28.2) 3 (25.0) 1 (33.3) 5 (31.3) 0.42 (0.08–2.28) 0.313
BMI (kg/m2), mean ± SD 18.6 ± 2.7 17.5 ± 2.2 22.6 ± 0.5 19.3 ± 2.6 0.78 (0.64–0.96) 0.017
F508del mutation
Homozygous (yes) 16 (41.0) 9 (45.0) 2 (66.7) 5 (31.3) 1.10 (0.44–2.72) 0.843
Heterozygous (yes) 12 (30.8) 6 (30.0) 1 (33.3) 5 (31.3) 1.07 (0.41–2.81) 0.886
Pancreatic insufficiency (yes) 35 (89.7) 20 (100.0) 3 (100.0) 12 (75.0) 0.04 (0.00–11.4) 0.261
CFRD (yes) 16 (41.0) 9 (45.0) 1 (33.3) 6 (37.5) 0.78 (0.31–1.94) 0.590
Any pneumothorax (yes) 8 (20.5) 6 (30.0) 0 (0.0) 2 12.5) 0.48 (0.18–1.29) 0.145
Major haemoptysis > 100mL (yes) 12 (30.8) 6 (30.0) 1 (33.3) 5 (31.3) 1.44 (0.52–3.99) 0.489
Bronchial artery embolization (yes) 8 (20.5) 3 (15.0) 1 (33.3) 4 (25.0) 2.37 (0.55–10.26) 0.250
CF liver disease (yes) 18 (46.2) 12 (60.0) 1 (33.3) 5 (31,3) 0.53 (0.22–1.30) 0.164
Liver transplant (yes) 1 (2.6) 1 (5.0) 0 (0.0) 0 (0.0) 0.29 (0.04–2.30) 0.241
ABPA (yes) 8 (20.5) 3 (15.0) 0 (0.0) 5 (31.3) 1.94 (0.56–6.70) 0.296
DIOS (yes) 2 (5.1) 1 (5.0) 0 (0.0) 1 (6.3) 1.82 (0.24–13.85) 0.561
P. aeruginosa (yes) 35 (89.7) 19 (95.0) 3 (100.0) 13 (81.3) 0.29 (0.04–2.21) 0.234
S. aureus (yes) 30 (76.9) 17 (85.0) 2 (66.7) 11 (68.8) 0.52 (0.15–1.78) 0.295
MRSA (yes) 19 (48.7) 13 (65.0) 0 (0.0) 6 (37.5) 0.54 (0.21–1.35) 0.185
B. cepacia (yes) 18 (46.2) 10 (50.0) 0 (0.0) 8 (50.0) 1.13 (0.45–2.83) 0.799
NTM (yes) 1 (2.6) 0 (0.0) 0 (0.0) 1 (6.3)
Entry date in the study 1.11 (0.44–2.81) 0.827
≤ 2007 11 (28.2) 7 (35.0) 0 (0.0) 4 (25.0)
> 2007 28 (71.8) 13 (65.0) 3 (100.0) 12 (75.0)
Data are presented as n (%), median ± standard deviation or median (interquartile range). Hazard ratios (HRs) were derived from Cox regression models. CI
confidence interval, BMW Brazilian minimum wage, BMI body mass index, CFRD cystic fibrosis related diabetes, ABPA allergic bronchopulmonary aspergillosis, DIOS
distal Intestinal obstruction syndrome, MRSA methicillin-resistant Staphylococcus aureus, NTM non-tuberculous mycobacteria
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kg/m2 and BMI ≥ 18.5 kg/m2. Mean survival in patients
with BMI < 18.5 kg/m2 was 39.9 (95% CI = 25.8–54.0)
months (median survival was 36 motnhs, 95% CI = 18.7–
53.3) and in patients with BMI ≥ 18.5 kg/m2 mean
survival was 65.5 (95% CI = 49.2–81.8) months (median
survival not measurable), Log-rank test P = 0.028.
Discussion
In this retrospective cohort study, we demonstrated that
the median survival of CF subjects with FEV1 < 30% of
predicted was 37months. The main factors associated
with time to death while in the study were BMI and
tobramycin inhalation therapy. In ROC curve analysis
for BMI, the best cut-off point selected was 18.5 kg/m2.
Mean survival in patients with BMI < 18.5 kg/m2 was sig-
nificantly lower (39.9 months) than in patients with
BMI ≥ 18.5 kg/m2 (65.5 months). At the end of the study
period, 20 (51.3%) died, 16 subjects (41.0%) underwent
bilateral lung transplantation, and 3 subjects were alive
and still waiting for lung transplantation. There was no
difference between patients with entry date in the study
after 2007 from those with entry date in 2007 or before.
A measurement of lung function over time to assess
disease progression has been the most useful predictor
[5]. In 1992, Kerem et al. [14] reported that FEV1 < 30%
of predicted was associated with a 2-year mortality rate
of approximately 50% (38% in men and 56% in women).
Milla et al. [15] analysed CF patients who reached and
kept an FEV1 < 30% predicted. The median survival was
3.9 years and only the rate of decline in percent of pre-
dicted FEV1 was a significant predictor of the risk of
death. Vizza et al. [10] studied a cohort of 146 patients
with CF who were listed for lung transplantation.
Thirty-seven patients died while waiting, 76 underwent
transplantation, and 33 were alive and still waiting. A
multivariate model identified shorter six-minute walk
distance, higher PASP, and diabetes mellitus as signifi-
cant risk factors for death on the waiting list.
Augarten et al. [16] evaluated 40 CF patients with
FEV1 less than 30% predicted. Out of them, 9 patients
were transplanted. CF patients with a FEV1 < 30% and
Table 2 Pulmonary function tests, 6-min walk distance and pulmonary artery systolic pressure estimated by echocardiography at
the entry date and associations with case status (death)
All Death Survival Transplant HR (95% CI) p-values
Subjects (n) 39 20 (51.3) 3 (7.7) 16 (41.0)
FVC (% predicted) 40.5 ± 10.3 42.6 ± 12.9 35.7 ± 4.1 38.9 ± 8.4 1.00 (0.96–1.05) 0.837
FEV1 (% predicted) 24.4 ± 3.9 24.3 ± 4.2 23.3 ± 4.6 24.8 ± 3.7 0.95 (0.84–1.07) 0.362
FEV1 /FVC (%) 54.7 ± 9.4 53.6 ± 10.5 55.4 ± 3.5 55.9 ± 8.9 0.98 (0.93–1.04) 0.507
SpO2 (%) 91.6 ± 4.3 92.7 ± 3.3 87.3 ± 4.5 91.2 ± 5.1 1.03 (0.91–1.2) 0.629
6-MWT (m) 479.9 ± 104.8 481.7 ± 115.3 514.0 ± 51.9 471.6 ± 103.9 0.99 (0.99–1.00) 0.840
PASP ≥ 35mmHg (yes) 15 (38.5) 6 (30.0) 1 (33.3) 8 (50.0) 2.17 (0.83–5.72) 0.116
Data are presented as n (%) or median ± standard deviation. Hazard ratios (HRs) were derived from Cox regression models. CI confidence interval, FVC forced vital
capacity, FEV1 forced expiratory volume in the first second, SpO2 room air saturation of peripheral oxygen (evaluated by a non-invasive pulse oximeter), 6-MWd 6-
min walk distance, PASP pulmonary artery systolic pressure
Table 3 Therapeutic support at the entry date and associations with case status (death)
All Death Survival Transplant HR (95% CI) p-values
Subjects (n) 39 20 (51.3) 3 (7.7) 16 (41.0)
Dornase alfa (yes) 39 (100.0) 20 (100.0) 3 (100.0) 16 (100.0) – –
Colistin inhalation (yes) 38 (97.4) 20 (100.0) 2 (66.7) 16 (100.0) 0.05 (0.0–472.26) 0.511
Tobramycin inhalation (yes) 19 (48.7) 15 (75.0) 1 (33.3) 3 (18.8) 3.82 (1.38–10.60) 0.010
Azithromycin (yes) 33 (84.6) 16 (80.0) 3 (100.0) 14 (87.5) 1.32 (0.44–4.01) 0.622
Oxygen therapy (yes) 19 (48.7) 10 (50.0) 3 (100.0) 6 (37.5) 0.55 (0.22–1.36) 0.191
Pulmonary Exacerbations in the last year, median IR) 3 (1) 3 (1) 2(0) 3 (3) 0.86 (0.61–1.21 0.392
Hospital admission in the last year (n), median (IR) 2.1 (2.0) 2.0 (2.0) 0 (0.0) 2.0 (1.0) 1.21 (0.91–1.61) 0.198
NIMV in the last year (yes) 6 (15.4) 2 (10.0) 1 (33.3) 3 (18.8) 0.73 (0.17–3.23) 0.692
ICU admission in the last year (yes) 7 (17.9) 2 (10.0) 1 (33.3) 4 (25.0) 0.75 (0.17–3.43) 0.713
Mechanical ventilation (yes) 5 (12.8) 2 (10.0) 1 (33.3) 2 (12.5) 2.33 (0.51–10.8) 0.278
Data are presented as n (%), median ± standard deviation or median (interquartile range). Hazard ratios (HRs) were derived from Cox regression models. CI
confidence interval, NIMV non-invasive mechanical ventilation, ICU intensive care unit
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who did not receive a lung transplant had survived lon-
ger than CF patients who did receive a lung transplant
(median survival 7.33 vs. 3.49 year, 5-yr survival 73% vs.
29%). Two factors (rate of decline in FEV1 values and
age < 15 year) were found to influence the mortality rate.
George et al. [12] evaluated 276 adult CF patients in
London, whose FEV1 was first observed to be less than
30% predicted. Median survival improved from 1.2 years
in the 1990 group to 5.3 years in the 2002 group, with a
marked improvement in survival from 1994. The use of
nebulised recombinant human DNase was significantly
associated with a reduced risk of death (HR = 0.59, 95%
CI = 0.44–0.79). Significantly increased risks were associ-
ated with a BMI under 19 (HR = 1.52, 95% CI = 1.10 to
2.10), long term oxygen therapy (HR = 3.52, 95% CI =
2.49–4.99), and nebulised antibiotics (HR = 1.84, 95%
CI = 1.05–3.22).
Ramos et al. [11] conducted a retrospective cohort
study using the CF Foundation Patient Registry from
2003 to 2013, including 3340 adult patients with a
FEV1 < 30% prior to lung transplant. Median transplant-
free survival was 6.6 years. There was substantial hetero-
geneity in survival, with some patients with CF dying
soon after reaching this lung function threshold and
others living for many years.
Another study reported a relationship between early
mortality and FEV1 < 30% of predicted and elevated
PaCO2 > 50mmHg [16]. In a 5-year survival model, an-
other study evaluated the impact of different variables
on survival and correlated it with a change in the FEV1
percentage predicted. Female sex, diabetes mellitus, B.
cepacia infection, and the number of exacerbations
negatively affected the survival of patients with CF,
whereas FEV1 percentage predicted alone was not a
sufficient predictor of early mortality [17].
The importance of heterogeneity of the disease and
inter-population variations in determining the survival
in adult CF patients in different populations was
highlighted by a recent report [4]. In contrast to these
previous studies, in the current study we demonstrated
that the median survival (37 months) was below that
expected. We could hypothesize that some of the factors
related with this worse prognosis are late diagnosis, poor
socioeconomic conditions and genetic aspects [18]. It is
suggested that further studies are conducted with other
larger samples and including other regions of Brazil.
Prior studies evaluating survival in patients with CF
have also documented increased risk of death among
patients with lower BMI [11, 14, 19]. Ramos et al. [11]
observed a high mortality associated with a BMI < 18 kg/
m2.
In Brazil, the public health system provides ambulatory
and hospital health carefree of charge. Also, CF medica-
tions are available through the public health system
known as SUS (Sistema Único de Saúde) entirely free of
any cost. Some CF medications are part of a protocol of
medications that have been approved by Brazilian Health
Ministry. The Health Secretary of each state is respon-
sible for the delivery of the medications through public
health care units or through public pharmacies. Usually,
the CF care (CF Centers) is performed in each state in
public hospital or university hospital. During the period
of the study, the following medications were available:
alfa dornase, colistin, tobramycin solution for inhalation,
Fig. 1 a Kaplan-Meier analysis of survival effect in cystic fibrosis patients with FEV1 < 30%. Median survival was 37 (CI = 16.4–57.6) months and
mean survival was 50.5 (CI = 39.3–61.6) months. b Kaplan-Meier survival functions comparing body mass index (BMI) < 18.5 kg/m2 and BMI≥ 18.5
kg/m2 in patients with cystic with FEV1 < 30%. Mean survival in patients with BMI < 18.5 kg/m2 = 39.9 (CI 25.8–54.0) months (median survival = 36
monhs, CI = 18.7–53.3) and in patients with BMI≥ 18.5 kg/m2 median survival = 65.5 (CI 49.2–81.8) months (median survival not measurable), Log-
rank test P = 0.028
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pancreatic enzymes, fat-soluble vitamins (A, D, E and
K), ursodeoxicolic acid, azithromycin, dietary supple-
ments, oral antibiotics for pulmonary infectious exacer-
bation. During the period of the study, new therapies
such ivacaftor and ivacaftor/lumacaftor had not yet been
approved in Brazil. State of Rio Grande do Sul, in south-
ern Brazil, has a total area of around 281,748 km2 and
11.29 million inhabitants. There are three CF centers in
Rio Grande do Sul, all of them located in the capital
Porto Alegre. Almost all patients attending the Adult CF
Centre of HCPA were from were living in the state of
Rio Grande do Sul.
In Brazil there are six lung transplantation centers,
two of them located in Porto Alegre. In Brazil, lung
transplantation candidates are listed according to the
chronological criterion. When there is organ supply, ac-
tive patients compete according to waiting list time, pro-
vided there is ABO blood group identification, ribcage
size compatibility, updated immunological reactivity test
and, eventually, ABO compatibility (in the absence of re-
ceptors with the same ABO blood group as the donor).
Patients who receive an organ that does not function
within the first 48 h are an exception to the criteria
above. In these situations, these receptors can be listed
to receive another organ with urgency, being automatic-
ally placed at the top of the list [20]. The mean time on
the waiting list for lung transplantation during the
period of the study was approximately 18 months [21].
Guidelines recommend tobramycin solution for inhal-
ation in patients over 6 years with chronic P. aeruginosa
[22]. Colistin is used widely in Europe to treat chronic
bacterial infection with Pseudomonas aeruginosa. In
Brazil, inhaled colistin therapy is less expensive then in-
haled tobramycin [23]. So, during the period of the
study, in our institution the first option to treat chronic
infection with P. aeruginosa was colistin. We reserved
the use of inhaled tobramycin for patients with advanced
lung disease. Consequently, patients who receive inhaled
tobramycin in our service are more likely to have worse
disease severity. The association of tobramycin inhal-
ation with time to death in the present study could
interpreted as confounding by severity [24].
The present study has some potential limitations. First,
the investigation was done in a single centre. Second,
the sample size was too small and would be associated
with low statistical power. Mainly, because too many
variables entered Cox regression models. Third, the
retrospective study design did not allow us to assess
some potential risk factors for mortality (parameters that
were not collected).
The clinical relevance of the present study is to alert
Brazilian adult CF physicians to the lower survival rate
of adult CF subjects with FEV1 < 30% of predicted. Also,
the association with a long time in lung transplant
waiting list, should suggest that early referral for consid-
eration of lung transplantation is highly desirable.
Conclusion
In conclusion, we demonstrated that the median survival
of CF subjects with FEV1 < 30% of predicted was 37
months. The main factors associated with time to death
while in the study were BMI and tobramycin inhalation
therapy. The best cut-off point selected for BMI was
18.5 kg/m2. Mean survival in patients with BMI < 18.5
kg/m2 was significantly lower (39.9 months) than in pa-
tients with BMI ≥ 18.5 kg/m2 (65.5 months). It is hoped
that targeting these individuals for more intense nutri-
tional optimisation will improve the survival.
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